Niagen Bioscience CFO granted 62,131 stock options

Pamir Ozan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Pamir Ozan reported acquisition or exercise transactions in this Form 4 filing.

Niagen Bioscience, Inc. reported that its Chief Financial Officer, Pamir Ozan, received a grant of employee stock options covering 62,131 shares of common stock. The options were awarded at no cost as part of his compensation.

According to the vesting terms, one-fourth of the options will vest on each anniversary of the grant date, spreading the potential ownership benefits over four years and tying them to continued service with the company.

Insider Trade Summary

Grant/Award: 62,131 shares

Grant/Award 1 txn

Insider Pamir Ozan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Options (right to buy)	62,131	$0.00	$0.00

Holdings After Transaction: Employee Stock Options (right to buy) — 62,131 contracts (Direct)

Footnotes (1)

1. F1. One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Niagen Bioscience (NAGE) report for Pamir Ozan?

Niagen Bioscience reported that CFO Pamir Ozan was granted employee stock options for 62,131 shares. These derivative securities give him the right to buy common stock under a vesting schedule tied to his continued service with the company.

How many stock options did Niagen Bioscience (NAGE) grant to its CFO?

The company granted CFO Pamir Ozan employee stock options covering 62,131 shares. All 62,131 options were acquired in a single grant and represent potential future ownership, depending on vesting and any future exercise decisions.

What is the vesting schedule for the Niagen Bioscience (NAGE) CFO’s options?

One-fourth of the shares subject to the option vest on each anniversary of the grant date. This four-year vesting structure is designed to reward long-term service and align the CFO’s incentives with the company’s ongoing performance.

Is the Niagen Bioscience (NAGE) CFO’s Form 4 transaction a purchase or a grant?

The transaction is a grant of employee stock options, classified as an acquisition under code “A.” It does not represent an open-market share purchase but an award of derivative securities as part of executive compensation.

How many Niagen Bioscience (NAGE) options does the CFO hold after this grant?

After the reported grant, Pamir Ozan beneficially holds 62,131 employee stock options. This total reflects the derivative securities following the transaction, subject to the multi-year vesting schedule described in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 04:46 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pamir Ozan

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (right to buy)	$4.94	02/19/2026		A		62,131		02/19/2027(1)	02/18/2036	Common Stock	62,131	$0	62,131	D

Explanation of Responses:

1. One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.